|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.64 USD | +5.57% |
|
+8.09% | -18.03% |
| 04/03 | NervGen Pharma Corp. Announces Executive Changes | CI |
| 04/03 | Sarepta Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM |
| Capitalization | 185.2Cr 159.76Cr 144.26Cr 138.26Cr 251.28Cr 17TCr 262.73Cr 1.7TCr 683.02Cr 8.16TCr 695.23Cr 680.28Cr 29TCr | P/E ratio 2026 * |
5.6x | P/E ratio 2027 * | 14x |
|---|---|---|---|---|---|
| Enterprise value | 138.96Cr 119.87Cr 108.24Cr 103.74Cr 188.53Cr 13TCr 197.13Cr 1.28TCr 512.48Cr 6.12TCr 521.64Cr 510.42Cr 22TCr | EV / Sales 2026 * |
0.8x | EV / Sales 2027 * | 0.77x |
| Free-Float |
95.63% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sarepta Therapeutics, Inc.
| 1 day | +5.57% | ||
| 1 week | +8.09% | ||
| Current month | +5.25% | ||
| 1 month | -3.66% | ||
| 3 months | -20.43% | ||
| Current year | -18.03% |
| 1 week | 15.52 |  | 17.71 |
| 1 month | 15.52 | | 19.25 |
| Current year | 15.52 | | 24.68 |
| 1 year | 10.42 | | 103.32 |
| 3 years | 10.42 | | 173.25 |
| 5 years | 10.42 | | 173.25 |
| 10 years | 8 | | 181.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 63 | 26/06/2017 |
Ryan Wong
DFI | Director of Finance/CFO | 47 | 16/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 50 | 14/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 73 | 16/04/2015 |
| Director/Board Member | 87 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 67 | 02/06/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 4.63% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +5.57% | +8.09% | -82.88% | -88.12% | 185.2Cr | |
| +6.40% | -1.78% | -41.46% | -43.36% | 218.03Cr | |
| -2.38% | -5.16% | +9.67% | -23.97% | 37Cr | |
| -4.93% | -9.76% | -31.33% | - | 7.31Cr | |
| Average | +1.16% | -1.32% | -36.50% | -51.81% | 111.78Cr | |
| Weighted average by Cap. | +5.15% | +2.01% | -54.26% | -60.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 173.15Cr 149.36Cr 134.87Cr 129.26Cr 234.92Cr 16TCr 245.63Cr 1.59TCr 638.57Cr 7.63TCr 649.98Cr 636.01Cr 27TCr | 144.42Cr 124.58Cr 112.49Cr 107.81Cr 195.94Cr 13TCr 204.87Cr 1.33TCr 532.61Cr 6.36TCr 542.13Cr 530.48Cr 23TCr |
| Net income | 35Cr 30Cr 27Cr 26Cr 47Cr 3.18TCr 49Cr 317.31Cr 127.25Cr 1.52TCr 129.52Cr 126.74Cr 5.46TCr | 9.31Cr 8.03Cr 7.26Cr 6.95Cr 13Cr 858.14Cr 13Cr 86Cr 34Cr 410.49Cr 35Cr 34Cr 1.47TCr |
| Net Debt | -46Cr -40Cr -36Cr -35Cr -63Cr -4.26TCr -66Cr -425.28Cr -170.55Cr -2.04TCr -173.59Cr -169.86Cr -7.31TCr | -74Cr -64Cr -58Cr -55Cr -100.67Cr -6.84TCr -105.26Cr -682.39Cr -273.65Cr -3.27TCr -278.54Cr -272.55Cr -12TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/26/09 | 17.64 $ | +5.57% | 37,25,892 |
| 06/26/06 | 16.71 $ | +2.96% | 30,69,287 |
| 05/26/05 | 16.23 $ | +0.87% | 24,86,480 |
| 04/26/04 | 16.09 $ | +1.39% | 20,72,962 |
| 03/26/03 | 15.87 $ | -2.76% | 20,15,676 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition